.Attributes Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA study, after a mean follow-up of 11 months, patients along with metastatic intestinal tumors who got biomarker-matched treatments based on flowing lump DNA profiling revealed a more significant scientific benefit than those acquiring unequaled treatment.